Aktuellt
SENASTE
Redeye comments on Fluoguide’s Q4 report, following a relatively calm couple of months on the news front. However, the company faces multiple potential catalysts during 2022, including high-grade glioma and NSCLC phase II readouts. The share has taken some beating recently, and we believe a lower share price and multiple upcoming catalysts could provide an attractive entry point.
LÄS MER
